Macrocyclic compounds useful as pharmaceuticals

Details Macrocyclic compounds useful as pharmaceuticals Macrocyclic compounds useful as pharmaceuticals

2011-03-29

2011-03-29

Oh, Taylor Victor (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S450000

Reexamination Certificate

active

07915306

ABSTRACT:
The present invention provides compositions comprising compounds having formula (I):and additionally provides methods for the use thereof in the treatment of various disorders including inflammatory or autoimmune disorders, and disorders involving malignancy or increased angiogenesis, wherein R1-R11, X, Y, Z, and n are as defined herein. In certain embodiments, the compositions are for systemic (e.g., oral) administration. In certain embodiments, methods for the treatment of various disorders including inflammatory or autoimmune disorders comprise systemically (e.g., orally) administering to a subject in need thereof a therapeutically effective amount of a compound of formula (I).

REFERENCES:
patent: 5674892 (1997-10-01), Giese et al.
patent: 5728726 (1998-03-01), Giese et al.
patent: 5795910 (1998-08-01), Giese et al.
patent: 6265603 (2001-07-01), Lewis et al.
patent: 2006/0247448 (2006-11-01), Boivin et al.
patent: 0 606 044 (1993-11-01), None
patent: 2 323 845 (1998-10-01), None
patent: 6-228122 (1994-08-01), None
patent: 8-40893 (1996-02-01), None
patent: 10-508024 (1998-08-01), None
patent: 2001-294527 (2001-10-01), None
patent: 2004-292314 (2004-10-01), None
patent: 2004-292315 (2004-10-01), None
patent: WO 96/13259 (1996-05-01), None
patent: WO 00/38674 (2000-07-01), None
patent: WO 00/39314 (2000-07-01), None
patent: WO 01/36003 (2001-05-01), None
patent: WO-02/48135 (2002-06-01), None
patent: WO 02/48136 (2002-06-01), None
patent: WO-02/48136 (2002-06-01), None
patent: WO03/076424 (2003-09-01), None
Zhao et al, J. Antibiot., vol. 52(12), pp. 1086-1094, 1999.
Anne Dombrowski, Rosalind Jenkins, Susan Raghoobar, Gerald Bills, Jon Polishook, Fernando Pelaez, Bruce Burgess, Annie Zhao, Leeyuan Huan, Yan Zhang & Michael Goetz, Production of a Family of Kinase-Inhibiting Lactones from Fungal Fermentations, The J. Antibiot., 52:12, 1077-85 (1999).
George A. Patani & Edmond J. LaVoie, Bioisosterism: A Rational Approach in Drug Design, Chem. Rev. 96:3147-76 (1996).
David B.R. Johnston, Carol A. Sawicki, T.B. Winndholz, and A.A. Patchett, Synthesis of Dideoxyzearalanone and Hydroxyl Derivatives, J. Med. Chem., 13(5):941-44 (1970).
International Search Report for PCT/US03/07377.
Agatsuma, et al., “Revised Structure and Stereochemistry of Hypothemycin”,Chem.Pharm.Bull.; 41(2): 373-375 1993.
Chen, et al., “Activation of p38 MAP kinase and ERK are required for ultraviolet-B induced c-fosgene expression in human keratinocytes”,Oncogene, 18: 7649-7476, 1999.
Dombrowski, et al., “Production of a Family of Kinase-inhibiting Lactones from Fungal Fermentations”,J. Antibiot., 52(12): 1077-1085, 1999.
Ellestad, et al., “New Zearalenone Related Macrolides and Isocoumarins from an Unidentified Fungus”,J. Org. Chem., 43(12):2339-2343, 1978.
Li, et al., “Rays and arrays: the transcriptional program in the response of human epidermal keratinocytes to UVB illumination”,The FASEB Journal, Article 10.1096/fj.01-0172fje, published online Sep. 17, 2001.
Kastelic, et al., “Induction of Rapid IL=1β mRNA Degradation in THP-1 Cells Mediated Through the AU-Rich Region in the 3'UTR by a Radicocol Analogue”,Cytokine8(10): 751-761, 1996.
Matsuoka, et al., “Inhibition of HgCl2-induced mitogen-activated protein kinase activation by LL-Z1640-2 in CCRF-CEM cells”,Eur. J. Pharmacol., 409(2): 155-158, 2000.
Rawlins, et al., “Inhibition of endotoxin-induced TNF-α production in macrophages by 5Z-7-oxo-zeaenol and other fungal resorcylic acid lactones”,Int. J. Immunopharmacol., 21(12): 799-814, 1999.
Tak, et al., “NF-κB-a key role in inflammatory diseases”,J. Clin.Investigation, 107(1): 7-11, 2001.
Takehana, et al., “A radicicol-Related Macrocyclic Nonaketide Compound, Antibiotic LL-Z1640-2, Inhibits theJNK/p38 Pathways in Signal-Specific Manner”,Biochem. Biophys. Res. Commun.,, 257(1): 19-23, 1999.
Tatsuta, et al., “The First Total Synthesis of a Macrocyclic Anti-protozoan, LL-Z1640-2”,Chem. Lett., vol. 2, 172-173, 2001.
Yamamoto, et al., “Therapeutic potential of inhibitionof the NF-κB pathway in the treatment of inflammation and cancer”,J. Clin.Investigation, 107(2), 135-142, 2001.
Lala et al., Cancer and Metastasis Reviews (1998), 17(1), 91-106.
“Protein Kinase” [online], (retrieved Sep. 8, 2008) URL: <http://en.wikipedia.org/wiki/Protein—Kinase>.
“Cancer” [online], (retrieved Jul. 6, 2007) URL: <http://en.wikipedia.org/wiki/Cancer>.
Golub et al., Science (1999), vol. 286, 531-37.
“Cancer” [online], (retrieved Jul. 6, 2007) URL: <http://www.nlm.nih.gov/medlineplus/cancer.html>.
“Sun Exposure and Skin Cancer” [online], p. 1, (retrieved Sep. 8, 2008) URL: <http:/www.medicinenet.com/script/main/art.asp?Ii=USA&articlekey=43077&page=1>.
“Sun Exposure and Skin Cancer” [online], p. 2, (retrieved Sep. 8, 2008) URL: <http:/www.medicinenet.com/script/main/art.asp?Ii=USA&articlekey=43077&page=2>.
Partial file history for U.S. Appl. No. 10/507,067, documents dating from Sep. 8, 2004 through Mar. 10, 2009.
U.S. Office Action for related U.S. Appl. No. 10/507,067, dated Jun. 23, 2009.
Japanese Office Action for Application No. 2003-574642, dated Jul. 15, 2009.

Affiliated with

Also associated with

Rating

Macrocyclic compounds useful as pharmaceuticals does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Macrocyclic compounds useful as pharmaceuticals, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Macrocyclic compounds useful as pharmaceuticals will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2667797